Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Pamoda Mahishi Galhenage, Ph.D.

Concepts (12)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Pamoda Galhenage's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Pamoda Galhenage has written about over time.
Disease Models, Animal, 1 publications between 2020 and 2020, average publication date November 2020. Drug Therapy, Combination, 1 publications between 2020 and 2020, average publication date November 2020. Fallopian Tube Neoplasms, 1 publications between 2020 and 2020, average publication date November 2020. Mice, Transgenic, 1 publications between 2020 and 2020, average publication date November 2020. Animals, 2 publications between 2020 and 2023, average publication date April 2022. Cystadenocarcinoma, Serous, 2 publications between 2020 and 2023, average publication date April 2022. Female, 2 publications between 2020 and 2023, average publication date April 2022. Ovarian Neoplasms, 2 publications between 2020 and 2023, average publication date April 2022. Epithelial Cells, 1 publications between 2023 and 2023, average publication date September 2023. Fallopian Tubes, 1 publications between 2023 and 2023, average publication date September 2023. Humans, 1 publications between 2023 and 2023, average publication date September 2023. Mice, 1 publications between 2023 and 2023, average publication date September 2023.

To see the data from this visualization as text, click here.
Galhenage's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (12)
Explore
_
Co-Authors (3)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.